Debbie Rigby rounds up the latest in research news
UK research data for over 20,000 patients shows use of gliptins or glitazones is associated with decreased risks of heart failure, cardiovascular disease, and all cause mortality compared with non-use of these drugs in people with type 2 diabetes. Gliptins were significantly associated with an 18% decreased risk of all cause mortality, a 14% decreased risk of heart failure, and no significant change in risk of cardiovascular disease; corresponding values for glitazones were significantly decreased risks of 23% for all cause mortality, 26% for heart failure, and 25% for cardiovascular disease.
A large meta-analysis of 301 clinical trials has concluded that there are no significant differences in the associations between any of 9 available classes of glucose-lowering drugs (alone or in combination) and the risk of cardiovascular or all-cause mortality. Metformin was associated with lower or no significant difference in HbA1C levels compared with any other drug classes. All drugs were estimated to be effective when added to metformin.
A Cochrane review has found no evidence that one type of intranasal steroid is more effective than another in patients with chronic rhinosinusitis, nor that higher doses are better than lower, nor that the effectiveness of a spray differs from an aerosol. Epistaxis was more common when higher doses were used.
Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD011993.
Although guidelines recommend that blood pressure (BP) should be measured on a bare arm, BP is sometimes measured over clothing in clinical settings. This cross-sectional study to a total of 186 individuals shows significant differences in BP between the bare arm and over a cardigan sleeve or over a rolled-up cardigan sleeve. Systolic blood pressure varied by up to 15mmHg when taken over clothing.
Family Practice (2016). First published online: July 8, 2016